BioVerde Health Reports Positive Phase II Data for BV-401 in Pancreatic Cancer

BioVerde Health today announced positive topline results from its Phase IIa clinical trial evaluating BV-401, its lead oncology programme, in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

The trial met its primary endpoint of objective response rate (ORR), with BV-401 demonstrating an ORR of 34% in a heavily pre-treated population, compared to a historical benchmark of approximately 10-15% for standard second-line therapies.

Median progression-free survival was 5.8 months, and the safety profile was consistent with prior Phase I findings. No dose-limiting toxicities were observed at the recommended Phase II dose.

"These results represent a meaningful step forward for patients with one of the most challenging malignancies in oncology," said Chief Medical Officer Dr. Rui Costa. "We are engaging with regulators on the design of a registrational study."